| General Information | |
|---|---|
| ZINC ID | ZINC000027750192 |
| Molecular Weight (Da) | 339 |
| SMILES | CC1=CC[C@H]2[C@H](C1)c1c(O)cc(CC#CCCCN)cc1OC2(C)C |
| Molecular Formula | C22N1O2 |
| Action | Partial Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 98.17 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 25 |
| LogP | 4.703 |
| Activity (Ki) in nM | 1288.25 |
| Polar Surface Area (PSA) | 55.48 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | + |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | + |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.8587768 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 6 |
| Fraction csp3 | 0.55 |
| Ilogp | 3.85 |
| Xlogp3 | 5.35 |
| Wlogp | 4.37 |
| Mlogp | 3.65 |
| Silicos-it log p | 4.63 |
| Consensus log p | 4.37 |
| Esol log s | -5.29 |
| Esol solubility (mg/ml) | 0.00172 |
| Esol solubility (mol/l) | 0.00000507 |
| Esol class | Moderately |
| Ali log s | -6.27 |
| Ali solubility (mg/ml) | 0.000183 |
| Ali solubility (mol/l) | 0.00000054 |
| Ali class | Poorly sol |
| Silicos-it logsw | -5.25 |
| Silicos-it solubility (mg/ml) | 0.0019 |
| Silicos-it solubility (mol/l) | 0.00000558 |
| Silicos-it class | Moderately soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.57 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 0 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 2 |
| Leadlikeness number of violations | 1 |
| Synthetic accessibility | 4.43 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -2.83 |
| Logd | 3.763 |
| Logp | 5.642 |
| F (20%) | 0.98 |
| F (30%) | 0.588 |
| Mdck | - |
| Ppb | 87.09% |
| Vdss | 5.947 |
| Fu | 1.60% |
| Cyp1a2-inh | 0.692 |
| Cyp1a2-sub | 0.723 |
| Cyp2c19-inh | 0.96 |
| Cyp2c19-sub | 0.561 |
| Cl | 11.619 |
| T12 | 0.135 |
| H-ht | 0.9 |
| Dili | 0.191 |
| Roa | 0.903 |
| Fdamdd | 0.932 |
| Skinsen | 0.807 |
| Ec | 0.005 |
| Ei | 0.015 |
| Respiratory | 0.946 |
| Bcf | 1.776 |
| Igc50 | 4.382 |
| Lc50 | 5.146 |
| Lc50dm | 6.305 |
| Nr-ar | 0.094 |
| Nr-ar-lbd | 0.116 |
| Nr-ahr | 0.271 |
| Nr-aromatase | 0.255 |
| Nr-er | 0.262 |
| Nr-er-lbd | 0.425 |
| Nr-ppar-gamma | 0.174 |
| Sr-are | 0.766 |
| Sr-atad5 | 0.009 |
| Sr-hse | 0.329 |
| Sr-mmp | 0.805 |
| Sr-p53 | 0.41 |
| Vol | 376.157 |
| Dense | 0.902 |
| Flex | 0.176 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 2 |
| Acute aquatic toxicity | - |
| Toxicophores | 4 |
| Qed | 0.491 |
| Synth | 3.923 |
| Fsp3 | 0.545 |
| Mce-18 | 62.588 |
| Natural product-likeness | 2.303 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |